SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses
Angela R Branche; Nadine G Rouphael; David D Diemert; Ann R Falsey; Cecilia Losada; Lindsey R Baden; Sharon E Frey; Jennifer A Whitaker; Susan J Little; Evan J Anderson; Emmanuel B Walter; Richard M Novak; Richard Rupp; Lisa A Jackson; Tara M Babu; Angelica C Kottkamp; Anne F Luetkemeyer; Lilly C Immergluck; Rachel M Presti; Martin Backer; Patricia L Winokur; Siham M Mahgoub; Paul A Goepfert; Dahlene N Fusco; Elissa Malkin; Jeffrey M Bethony; Edward E Walsh; Daniel S Graciaa; Hady Samaha; Amy C Sherman; Stephen R Walsh; getahun Abate; Zacharoula Oikonomopoulou; Hana M El Sahly; Thomas CS Martin; Christina A. Rostad; Michael Smith; Benjamin G Ladner; Laura Porterfield; Maya Dunstan; Anna Wald; Tamia Davis; Robert L Atmar; Mark J Mulligan; Kirsten E Lyke; Christine M Posavad; Megan A Meagher; David S Stephens; Kathleen M Neuzil; Kuleni Abebe; Heather Hill; Jim Albert; Teri C Lewis; Lisa A Giebeig; Amanda Eaton; Antonia Netzl; Samuel Hedley Wilks; Sina Tureli; Mamodikoe Mahkene; Sonja Crandon; Marina Lee; Seema U Nayak; David C Montefiori; Mat Matkowski; Derek J Smith; Paul C Roberts; John H Beigel.
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-22277336
BackgroundProtection from SARS-CoV-2 vaccines wanes over time and is compounded by emerging variants including Omicron subvariants. This study evaluated safety and immunogenicity of SARS-CoV-2 variant vaccines. MethodsThis phase 2 open-label, randomized trial enrolled healthy adults previously vaccinated with a SARS-CoV-2 primary series and a single boost. Eligible participants were randomized to one of six Moderna COVID19 mRNA vaccine arms (50{micro}g dose) Prototype (mRNA-1273), Omicron BA.1+Beta (1 or 2 doses), Omicron BA.1+Delta, Omicron BA.1 monovalent, and Omicron BA.1+Prototype. Neutralization antibody titers (ID50) were assessed for D614G, Delta, Beta and Omicron BA.1 variants and Omicron BA.2.12.1 and BA.4/BA.5 subvariants 15 days after vaccination. ResultsFrom March 30 to May 6, 2022, 597 participants were randomized and vaccinated. Median age was 53 years, and 20% had a prior SARS-CoV-2 infection. All vaccines were safe and well-tolerated. Day 15 geometric mean titers (GMT) against D614G were similar across arms and ages, and higher with prior infection. For uninfected participants, Day 15 Omicron BA.1 GMTs were similar across Omicron-containing vaccine arms (3724-4561) and higher than Prototype (1,997 [95%CI1,482-2,692]). The Omicron BA.1 monovalent and Omicron BA.1+Prototype vaccines induced a geometric mean ratio (GMR) to Prototype for Omicron BA.1 of 2.03 (97.5%CI1.37-3.00) and 1.56 (97.5%CI1.06-2.31), respectively. A subset of samples from uninfected participants in four arms were also tested in a different laboratory at Day 15 for neutralizing antibody titers to D614G and Omicron subvariants BA.1, BA.2.12.2 and BA.4/BA.5. Omicron BA.4/BA.5 GMTs were approximately one third BA.1 GMTs (Prototype 517 [95%CI324-826] vs. 1503 [95%CI949-2381]; Omicron BA.1+Beta 628 [95%CI367-1,074] vs. 2125 [95%CI1139-3965]; Omicron BA.1+Delta 765 [95%CI443-1,322] vs. 2242 [95%CI1218-4128] and Omicron BA.1+Prototype 635 [95%CI447-903] vs. 1972 [95%CI1337-2907). ConclusionsHigher Omicron BA.1 titers were observed with Omicron-containing vaccines compared to Prototype vaccine and titers against Omicron BA.4/BA.5 were lower than against BA.1 for all candidate vaccines. Clinicaltrials.govNCT05289037
Texto completo
Documentos relacionados